A review of the current use of rituximab in autoimmune diseases - ScienceDirect
From IVIG to PEX to Rituximab to Helminths to treat PANS - Aspire
The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: a multicentre, non-randomised, open-label phase 2 study - eClinicalMedicine
Rituxan: Side effects and what to do about them
JCM | Free Full-Text | Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: Part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA)
Rituximab-abbs (Truxima) Drug Information
Rituxan: Side effects and what to do about them
RA | Safety Data & Possible Side Effects | RITUXAN® (rituximab)
Rituximab in MS | Experimental MS Treatments | Multiple Sclerosis News Today
Rituxan side effects and how to avoid them - NiceRx
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial - The Lancet Neurology
Chronic Fatigue Syndrome: Best Ways for Treating This Condition
Fibromyalgia vs. Lupus: What's the Difference?
My Experience with Rituximab | Neuromyelitis-Optica.net
Current evidence of rituximab in the treatment of multiple sclerosis - Multiple Sclerosis and Related Disorders
Ibrutinib–rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial - The Lancet Oncology
JCM | Free Full-Text | Fatigue in Systemic Lupus Erythematosus and Rheumatoid Arthritis: A Comparison of Mechanisms, Measures and Management
Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrome: a preliminary case series | BMC Neurology | Full Text
The Day After a Rituxan Infusion for Rheumatoid Arthritis
Rituxan Side Effects: Common, Severe, Long Term
Rituximab Fails in Chronic Fatigue | MedPage Today
Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial - The Lancet Respiratory Medicine